Cancer Gene Therapy
Introgen Announces Publication of Research Showing Promising Activity of INGN 241 Combined with Velcade(R) in Ovarian Cancer
Published in Gene Therapy Weekly, October 18th, 2007
Introgen Therapeutics, Inc. (NASDAQ:INGN) announced the publication of data from a preclinical study demonstrating the combination of INGN 241, Introgen's mda-7/IL-24 cancer product candidate, and Velcade(R) (Bortezemib) resulted in increased tumor cell killing in human ovarian cancer cells. The results from the study appeared in an advanced on-line article in Cancer Gene Therapy and provide a new molecularly targeted approach to specifically destroy cancer cells. The research was performed in the laboratory of Dr. Rajagopal Ramesh, associate professor in the Department of Thoracic and Cardiovascular Surgery at M.D. Anderson Cancer Center.
"This study shows that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-10-18)
More Articles from Gene Therapy Weekly
- Breast Cancer
Manchester researchers announce new methods of beating breast cancer - Antisense Technology
Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics - Bioengineering
AVEO Pharmaceuticals to Utilize Peptech's Breakthrough Technology to ''Humanise'' Internal Drug Candidates - Gene Therapy
OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration - Patents
Idera Pharmaceuticals Announces Issuance of US Patent for Novel Oligonucleotide Compositions Targeted to Toll-like Receptors - RNA Libraries
Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
